IRADIMED CORP

Company Overview

IRadimed Corporation is a small medical‑device manufacturer (Healthcare sector, Medical Devices industry) that designs, assembles and sells MRI‑compatible patient care products — principally the MRidium non‑magnetic IV infusion pump family, the 3880 MRI vital‑signs monitor, and related disposables, warranties and service. FY2024 revenue was $73.2M with strong gross margins (~77–79%) and operating income (30% margin); unit sales and U.S. demand drove recent growth while international revenue lagged. The company sells direct in the U.S. and through distributors internationally, holds ISO 13485/MDSAP certification, maintains a modest R&D program (~3.9% of revenue) and recently received 510(k) clearance for its next‑generation pump (May 29, 2025) with a staged commercial rollout. Operational risks include regulatory approval pathways, historically single‑sourced components (now largely in‑house), seasonal selling cycles and concentration in U.S. sales.

Executive Compensation Practices

Compensation for executives in this Medical Devices company is likely driven by device unit growth, U.S. revenue growth, gross margin and free cash flow — metrics highlighted in the filings — as well as recurring revenue from disposables, service and warranty streams that support sustained performance. Given the company’s strong margins, high operating cash flow and use of RSUs (filings note RSU‑related tax payments and dividends), pay packages will typically combine base salary, annual cash bonuses tied to short‑term sales/operating targets, and equity (RSUs/options) with multi‑year performance vesting tied to revenue, EPS, unit placements and/or commercial milestones (e.g., FDA clearances, new product ramps). Sales incentives and commission changes materially affected near‑term SG&A, so sales leadership pay is likely more variable and closely tied to unit bookings and disposables attach rates. Because IRadimed is smaller and capital needs (facility build, potential financing) are visible, boards may also use retention awards and milestone‑based equity to limit turnover and align management with long‑term commercialization goals.

Insider Trading Considerations

Insider trades at IRadimed can be informative but should be interpreted in light of common small‑cap device dynamics: insiders may sell routinely to cover RSU tax obligations or diversify (the company disclosed RSU tax payments and prior dividend activity), while purchases or abstentions around product rollouts or FDA milestones (e.g., the recent MRidium 3870 510(k)) can signal conviction. Material events that routinely trigger blackout windows include quarterly earnings, FDA submissions/clearances, major supply or facility developments, and potential capital raises (the company has an unused $75M shelf and has discussed possible equity or debt). Because U.S. sales are concentrated and float is modest, even small insider trades can move the stock; watch for Form 4 filings around earnings, product launch timelines, and any 10b5‑1 plan disclosures. Finally, regulatory and device‑safety issues (FDA guidance changes for infusion pumps, ISO certification status) create heightened risk for trading restrictions and potential clawback or holdbacks in incentive plans.